Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults.

[1]  D. Felmingham.  Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin. , 2002, The Journal of infection.

[2]  Antoine Andremont,et al.  Bronchopulmonary Disposition of the Ketolide Telithromycin (HMR 3647) , 2001, Antimicrobial Agents and Chemotherapy.

[3]  F. Vacheron,et al.  Lung concentrations of telithromycin after oral dosing. , 2001, The Journal of antimicrobial chemotherapy.

[4]  B. Lenfant,et al.  Pharmacokinetics of the New Ketolide Telithromycin (HMR 3647) Administered in Ascending Single and Multiple Doses , 2001, Antimicrobial Agents and Chemotherapy.

[5]  Michael J Fine,et al.  Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  A. Bryskier,et al.  Comparative Activities of Telithromycin (HMR 3647), Levofloxacin, and Other Antimicrobial Agents against Human Mycoplasmas , 2000, Antimicrobial Agents and Chemotherapy.

[7]  A. Schuchat,et al.  Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. , 2000, Archives of internal medicine.

[8]  D. Felmingham,et al.  The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. , 2000, The Journal of antimicrobial chemotherapy.

[9]  L. H. Hansen,et al.  The macrolide–ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA , 1999, Molecular microbiology.

[10]  P. Edelstein,et al.  In Vitro Activity of the Ketolide HMR 3647 (RU 6647) for Legionella spp., Its Pharmacokinetics in Guinea Pigs, and Use of the Drug To Treat Guinea Pigs withLegionella pneumophila Pneumonia , 1999, Antimicrobial Agents and Chemotherapy.

[11]  W. S. Champney,et al.  Inhibition of Translation and 50S Ribosomal Subunit Formation in Staphylococcus aureus Cells by 11 Different Ketolide Antibiotics , 1998, Current Microbiology.

[12]  O. Muller,et al.  Randomized, Multicentre Study of the Efficacy and Tolerance of Azithromycin versus Clarithromycin in the Treatment of Adults with Mild to Moderate Community-Acquired Pneumonia , 1998, European Journal of Clinical Microbiology and Infectious Diseases.

[13]  R. Daniel,et al.  Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia , 1998, European Journal of Clinical Microbiology and Infectious Diseases.

[14]  G. Eliopoulos,et al.  Susceptibilities of Legionella spp. to Newer Antimicrobials In Vitro , 1998, Antimicrobial Agents and Chemotherapy.

[15]  R. Jones,et al.  Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains. , 1998, Diagnostic microbiology and infectious disease.

[16]  R. Lütticken,et al.  In Vitro Activities of the New Ketolide Antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany , 1998, Antimicrobial Agents and Chemotherapy.

[17]  M. Hammerschlag,et al.  In Vitro Activity of a New Ketolide Antibiotic, HMR 3647, against Chlamydia pneumoniae , 1998, Antimicrobial Agents and Chemotherapy.

[18]  M. Jacobs,et al.  Susceptibilities of Penicillin- and Erythromycin-Susceptible and -Resistant Pneumococci to HMR 3647 (RU 66647), a New Ketolide, Compared with Susceptibilities to 17 Other Agents , 1998, Antimicrobial Agents and Chemotherapy.

[19]  H. Siegrist,et al.  Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia , 1997, European Journal of Clinical Microbiology and Infectious Diseases.

[20]  A. Maroli,et al.  Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia. , 1997, Clinical therapeutics.

[21]  R. N. Brogden,et al.  Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. , 1997, Drugs.

[22]  G. Gilbert,et al.  Rapid diagnosis of Legionella pneumophila serogroup 1 infection with the Binax enzyme immunoassay urinary antigen test , 1997, Journal of clinical microbiology.

[23]  Inger,et al.  A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.

[24]  T. Quinn,et al.  Diagnosis of Chlamydia pneumoniae infection in patients with community-acquired pneumonia by polymerase chain reaction enzyme immunoassay. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  A. Beunders.  Development of antibacterial resistance: the Dutch experience. , 1994, The Journal of antimicrobial chemotherapy.

[26]  J. Summersgill,et al.  Rapid, sensitive detection of Mycoplasma pneumoniae in simulated clinical specimens by DNA amplification , 1992, Journal of clinical microbiology.

[27]  T. Quinn,et al.  Identification of Chlamydia pneumoniae by DNA amplification of the 16S rRNA gene , 1992, Journal of clinical microbiology.

[28]  J. Enders.  Infectious Diseases Society of America , 1969 .

[29]  F. Baquero.  Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? , 1999, Journal of chemotherapy.

[30]  S. Coles,et al.  A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. , 1991, The Journal of antimicrobial chemotherapy.